Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business

RUTHERFORD, N.J., & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening Lōkahi’s growing network of partner academic institutions. The partnership with SDSU furthers Lōkahi’s work to identify and evaluate promising drug candidates and technologies that may have been overlooked or are no longer being actively developed. The program also supports Lōkahi’s efforts to explore potential new treatments while giving student participants practical experience addressing business challenges in the biopharmaceutical industry.

During its first year, the ai² Futures Lab™ engaged 64 students and identified more than 45 potential assets, several of which advanced into active pipeline discussions. The program expands Lōkahi’s sourcing reach and analytical capacity while supporting a disciplined, capital-efficient approach to pipeline development.

SDSU student participants will focus on therapeutic asset identification, evaluation, and strategic assessment, producing recommendations that may advance partnership discussions, licensing opportunities, or potential acquisition.

"The Fowler College of Business has a long tradition of preparing students to solve complex business challenges through hands-on learning and industry engagement," said Greg Tanneberger, J.D., Head of Corporate & Professional Education and Senior Program Administrator at SDSU Fowler College of Business. "Through the ai² Futures Lab™, our students will work on strategic opportunities at the intersection of business, innovation, and life sciences while contributing meaningful insights to asset evaluation and decision-making."

"The ai² Futures Lab™ was created to provide Lōkahi with a scalable, capital-efficient process for identifying and evaluating overlooked or strategically deprioritized therapeutic assets," said Brian Peters, Senior Vice President, ai² Division, Lōkahi Therapeutics™. "In our first year, participating teams identified more than 45 potential assets, with several advancing into active pipeline discussions. That represents encouraging early validation of the model and its ability to generate actionable opportunities for Lōkahi."

Adding SDSU further expands Lōkahi’s ai² Futures Lab™ network. Participating institutions may later expand into specialized business, clinical, technology, legal, or capital-focused tracks that support Lōkahi’s Discover, Advance, Monetize framework.

About Lōkahi Therapeutics™

Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com. For more information about the ai² Futures Lab program, please visit www.ai2futureslab.com.

About Glucotrack, Inc.

Glucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., focuses on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "anticipate,” "believe,” "expect,” "plan," and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations, or otherwise); the ability of Lōkahi Therapeutics™ to identify, evaluate, acquire, and advance therapeutic assets; the ability to maintain and expand academic and institutional partnerships; the ability to successfully integrate acquired assets into the company’s pipeline; general business and economic conditions; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.